Argus raises Pfizer stock price target on 2026 guidance boost
Argus raised its price target on Pfizer (PFE) to $40 from $35, citing increased 2026 revenue and EPS guidance. The stock trades at $30.79, near its 52-week high. Pfizer reported Q3 2026 earnings of $0.87 per share and $16.6B revenue, beating estimates. The company plans growth through R&D, new products, and acquisitions.
How this was made
The 30-second read
Why it matters
The analyst upgrade and higher guidance provide a fresh bullish catalyst for the stock, though short‑term price pressure is evident.
Market read
Primary earnings and guidance update for a large‑cap pharma stock, directly affecting its valuation.
What to watch
Potential patent expirations and pricing pressures could offset the upside.
Background
Pfizer reported Q3 2026 earnings that beat estimates and raised full‑year guidance, prompting Argus to lift its price target.
Ticker impact
Argus raised its price target on Pfizer to $40 and reported Q3 2026 earnings beat and higher guidance.
likely modest upside as market prices in the higher target
Analyst upgrade and stronger guidance provide a bullish catalyst, yet the stock slipped in pre‑market trading, tempering immediate moves.
Market effects
Boosts sentiment for the broader pharma sector as earnings beat and guidance raise expectations.
U.S. large‑cap health‑care index may see slight lift.
Limited to investors tracking major US drugmakers.
Counterpoint
The pre‑market decline suggests the market may be skeptical of the guidance sustainability.
Key entities
- companyPfizer Inc.
U.S. pharmaceutical giant reporting earnings and guidance.
- analyst_firmArgus Research
Raised price target on Pfizer.
